A s the annual Medicare open enrollment period unfolds, millions of Americans are evaluating their healthcare options for the ...
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
Conservative planning and continued business growth helped Molina keep an ongoing mismatch between payment rates and member ...
The presidential election, loss of higher federal funding, inflationary pressures and other challenges are leaving state ...
Medicaid expansion improved 2-year survival rates and access to guideline-concordant treatment for patients with HR-negative ...
Consensus is growing around the idea that for some patients higher doses of a gold-standard opioid addiction treatment drug ...
Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in ...
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...
In anticipation of the end of the COVID-19 public health emergency, Congress ended the Medicaid continuous coverage ...
Providers in many states can expect Medicaid reimbursement increases next year. Health insurance companies also are seeking ...
The Centers for Medicare & Medicaid Services (CMS) announced the approval of Medicaid coverage for Traditional Healing ...
Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback